HTF Market Intelligence released a new research report of 195 pages on title ‘Chronic Kidney Disease – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies.
Chronic Kidney Disease – Pipeline Review, H1 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease – Pipeline Review, H1 2017, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.
Request a sample report @ https://www.htfmarketreport.com/sample-report/398234-chronic-kidney-disease-pipeline-review
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 18, 1, 20 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
– The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Angion Biomedica Corp
apceth Biopharma GmbH
Astellas Pharma Inc
BLR Bio LLC
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Chugai Pharmaceutical Co Ltd
CTI BioPharma Corp
- Hoffmann-La Roche Ltd
Gilead Sciences Inc
GNI Group Ltd
Navya Biologicals Pvt Ltd
Nippon Zoki Pharmaceutical Co Ltd
Otsuka Holdings Co Ltd
Prismic Pharmaceuticals Inc
Prolong Pharmaceuticals LLC
ProMetic Life Sciences Inc
Reata Pharmaceuticals Inc
Regulus Therapeutics Inc
Spotlight Innovation Inc
Taisho Pharmaceutical Co Ltd
Toray Industries Inc
Unity Biotechnology Inc
VESSL Therapeutics Ltd
Vicore Pharma AB
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/398234-chronic-kidney-disease-pipeline-review
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Global Markets Direct Report Coverage 7
Chronic Kidney Disease (Chronic Renal Failure) – Overview 8
Chronic Kidney Disease (Chronic Renal Failure) – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Chronic Kidney Disease (Chronic Renal Failure) – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Chronic Kidney Disease (Chronic Renal Failure) – Companies Involved in Therapeutics Development 29
Angion Biomedica Corp 29
apceth Biopharma GmbH 29
Astellas Pharma Inc 30
AstraZeneca Plc 30
Bayer AG 31
BLR Bio LLC 31
Boehringer Ingelheim GmbH 32
Boryung Pharmaceutical Co Ltd 32
Cellmid Ltd 33
Chugai Pharmaceutical Co Ltd 33
Complexa Inc 34
Corvidia Corp 34
CTI BioPharma Corp 35
Evotec AG 35
- Hoffmann-La Roche Ltd 36
Gilead Sciences Inc 36
GNI Group Ltd 37
Lupin Ltd 37
Navya Biologicals Pvt Ltd 38
Nippon Zoki Pharmaceutical Co Ltd 38
Novartis AG 39
Otsuka Holdings Co Ltd 39
Prismic Pharmaceuticals Inc 40
Prolong Pharmaceuticals LLC 40
ProMetic Life Sciences Inc 41
Reata Pharmaceuticals Inc 41
Regulus Therapeutics Inc 42
Relypsa Inc 42
Resverlogix Corp 43
Spotlight Innovation Inc 43
Taisho Pharmaceutical Co Ltd 44
Toray Industries Inc 44
Tricida Inc 45
Unity Biotechnology Inc 45
Vascular BioSciences 46
VESSL Therapeutics Ltd 46
Vicore Pharma AB 47
Chronic Kidney Disease (Chronic Renal Failure) – Drug Profiles 48
(palmidrol + silibinin) – Drug Profile 48
ambrisentan – Drug Profile 49
ANG-3070 – Drug Profile 52
ANG-3281 – Drug Profile 53
ANG-3586 – Drug Profile 54
Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease – Drug Profile 55
apabetalone – Drug Profile 56
AS-2444697 – Drug Profile 68
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/398234-chronic-kidney-disease-pipeline-review
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=398234
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218